ArticleFrontiers in psychiatry2021
Non-targeted Metabolomics Profiling of Plasma Samples From Patients With Major Depressive Disorder.
Article in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Effect of whey protein-derived decapeptide on mood status and blood variables in healthy adults: a randomized, double-blind, placebo-controlled cross-over trial.European journal of nutrition · 2024Trial
- A Two-Level, Multidimensional Framework for Understanding and Treating Clinician Fatigue.Health care analysis : HCA : journal of health philosophy and policy · 2026Article
- Screening for peripheral blood biomarkers and construction of a diagnostic model for adolescent depression based on metabolomics and machine learning.BMC psychiatry · 2026Article
- Metabolomics biomarkers for precision psychiatry.Frontiers in psychiatry · 2026Review
- Fecal metabolites as early-phase biomarkers and prediction panel for ischemic stroke.BMC microbiology · 2025Article
- Plasma Lyso-PE 22:6 and Lyso-PE 20:4 are associated with development of mild to moderate depression revealed by metabolomics: a pilot study.BMC psychiatry · 2025Article
- Unusual Phospholipids fromJournal of the American Chemical Society · 2025Article
- Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification.Molecules (Basel, Switzerland) · 2024Review
- Oral D-ribose causes depressive-like behavior by altering glycerophospholipid metabolism via the gut-brain axis.Communications biology · 2024Article
- The neuropsychopharmacology of acetyl-L-carnitine (LAC): basic, translational and therapeutic implications.Discover mental health · 2024Review
- Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research.Molecules (Basel, Switzerland) · 2023Review
- Associations between prefrontal PI (16:0/20:4) lipid,Frontiers in psychiatry · 2023Article
- Discovery and validation of acetyl-L-carnitine in serum for diagnosis of major depressive disorder and remission status through metabolomic approach.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Major depressive disorder (MDD) is a neuropsychiatric disorder caused by multiple factors. Although there are clear guidelines for the diagnosis of MDD, the direct and objective diagnostic methods remain inadequate thus far. Methods: This study aims to discover peripheral biomarkers in patients with MDD and promote the diagnosis of MDD. Plasma samples of healthy controls (HCs, Results: Six differential metabolites were found by LC-MS/MS analysis. Three of these were increased, including L-aspartic acid (Asp), diethanolamine, and alanine. Three were decreased, including O-acetyl-L-carnitine (LAC), cystine, and fumarate. In addition, LAC, Asp, fumarate, and alanine showed large areas under the curve (AUCs) by ROC analysis. Conclusion: The study explored differences in peripheral blood between depressed patients and HCs. These results indicated that differential metabolites with large AUCs may have the potential to be promising biomarkers for the diagnosis of MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.